{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:20:10Z","timestamp":1791102010396,"version":"4.1.0"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,7,1]]},"DOI":"10.1097\/qai.0b013e31816fdc5f","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T13:39:52Z","timestamp":1236260392000},"page":"263-271","source":"Crossref","is-referenced-by-count":41,"title":["Host Genetic Influences on Highly Active Antiretroviral Therapy Efficacy and AIDS-Free Survival"],"prefix":"10.1097","volume":"48","author":[{"given":"Sher L","family":"Hendrickson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa P","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Phair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lautenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall C","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Kingsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph B","family":"Margolick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Detels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J","family":"Goedert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210131","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"R2-5-20210131","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm880","article-title":"Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.","volume":"9","author":"Siliciano","year":"2003","journal-title":"Nat Med"},{"key":"R3-5-20210131","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0140-6736(99)01122-8","article-title":"Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study.","volume":"353","author":"Ledergerber","year":"1999","journal-title":"Lancet"},{"key":"R4-5-20210131","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/00002030-200104130-00009","article-title":"Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study.","volume":"15","author":"Yamashita","year":"2001","journal-title":"AIDS"},{"key":"R5-5-20210131","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1097\/00002030-200107270-00006","article-title":"Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults.","volume":"15","author":"Bartlett","year":"2001","journal-title":"AIDS"},{"key":"R6-5-20210131","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1086\/315301","article-title":"Resistance profiles in patients with viral rebound on potent antiretroviral therapy.","volume":"181","author":"Cozzi","year":"2000","journal-title":"J Infect Dis"},{"key":"R7-5-20210131","first-page":"140","article-title":"Worldwide transmission of drug-resistant HIV.","volume":"5","author":"Wensing","year":"2003","journal-title":"AIDS Rev"},{"key":"R8-5-20210131","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(06)69152-6","article-title":"HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.","volume":"368","author":"May","year":"2006","journal-title":"Lancet"},{"key":"R9-5-20210131","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.med.54.101601.152346","article-title":"The influence of HLA genotype on AIDS.","volume":"54","author":"Carrington","year":"2003","journal-title":"Annu Rev Med"},{"key":"R10-5-20210131","doi-asserted-by":"crossref","first-page":"10002","DOI":"10.1073\/pnas.142313799","article-title":"Modulating influence on HIV\/AIDS by interacting RANTES gene variants.","volume":"99","author":"An","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"R11-5-20210131","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1034\/j.1600-065X.2000.17710.x","article-title":"The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS.","volume":"177","author":"OBrien","year":"2000","journal-title":"Immunol Rev"},{"key":"R12-5-20210131","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/ng1369","article-title":"Human genes that limit AIDS.","volume":"36","author":"OBrien","year":"2004","journal-title":"Nat Genet"},{"key":"R13-5-20210131","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.virol.2006.06.031","article-title":"Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection.","volume":"354","author":"Javanbakht","year":"2006","journal-title":"Virology"},{"key":"R14-5-20210131","doi-asserted-by":"crossref","first-page":"14053","DOI":"10.1128\/JVI.78.24.14053-14056.2004","article-title":"Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection.","volume":"78","author":"Martin","year":"2004","journal-title":"J Virol"},{"key":"R15-5-20210131","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1371\/journal.pgen.0030019","article-title":"Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals.","volume":"3","author":"An","year":"2007","journal-title":"PLoS Genet"},{"key":"R16-5-20210131","doi-asserted-by":"crossref","first-page":"6757","DOI":"10.1128\/JVI.00094-06","article-title":"Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1.","volume":"80","author":"Bashirova","year":"2006","journal-title":"J Virol"},{"key":"R17-5-20210131","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.med.54.101601.152346","article-title":"The influence of HLA genotype on AIDS.","volume":"54","author":"Carrington","year":"2003","journal-title":"Annu Rev Med"},{"key":"R18-5-20210131","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"R19-5-20210131","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1073\/pnas.0307067101","article-title":"Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a h5701 and a haplotypic Hsp70-Hom variant.","volume":"101","author":"Martin","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"R20-5-20210131","first-page":"323","article-title":"Positive influence of the Delta32CCR5 allele on response to highly active antiretroviral therapy (HAART) in HIV-1 infected patients.","volume":"5","author":"Kasten","year":"2000","journal-title":"Eur J Med Res"},{"key":"R21-5-20210131","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/00002030-200005050-00008","article-title":"Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy.","volume":"14","author":"OBrien","year":"2000","journal-title":"AIDS"},{"issue":"Suppl 4","key":"R22-5-20210131","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1097\/00002030-200317004-00006","article-title":"The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy.","volume":"17","author":"Tang","year":"2003","journal-title":"AIDS"},{"key":"R23-5-20210131","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1468-1293.2004.00219.x","article-title":"Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type.","volume":"5","author":"Bogner","year":"2004","journal-title":"HIV Med"},{"key":"R24-5-20210131","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/aid.2006.22.153","article-title":"Analysis of CCR5, CCR2, CX3CR1, and SDF1 polymorphisms in HIV-positive treated patients: impact on response to HAART and on peripheral T lymphocyte counts.","volume":"22","author":"Puissant","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R25-5-20210131","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1086\/345677","article-title":"CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients.","volume":"186","author":"Wit","year":"2002","journal-title":"J Infect Dis"},{"key":"R26-5-20210131","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jcv.2004.05.021","article-title":"CCR2-64I and CXCL12 3A alleles confer a favorable prognosis to AIDS patients undergoing HAART therapy.","volume":"34","author":"Passam","year":"2005","journal-title":"J Clin Virol"},{"key":"R27-5-20210131","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00002030-200301240-00010","article-title":"Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response.","volume":"17","author":"Brumme","year":"2003","journal-title":"AIDS"},{"key":"R28-5-20210131","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/324427","article-title":"Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.","volume":"184","author":"Lathey","year":"2001","journal-title":"J Infect Dis"},{"key":"R29-5-20210131","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1086\/496893","article-title":"Stromal cell-derived factor-1 genotype, coreceptor tropism, and HIV type 1 disease progression.","volume":"192","author":"Daar","year":"2005","journal-title":"J Infect Dis"},{"key":"R30-5-20210131","doi-asserted-by":"crossref","first-page":"14467","DOI":"10.1073\/pnas.97.26.14467","article-title":"Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10.","volume":"97","author":"Shin","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"R31-5-20210131","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1086\/376455","article-title":"A tumor necrosis factor-alpha-inducible promoter variant of interferon-gamma accelerates CD4+ T cell depletion in human immunodeficiency virus-1-infected individuals.","volume":"188","author":"An","year":"2003","journal-title":"J Infect Dis"},{"key":"R32-5-20210131","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1126\/science.270.5243.1811","article-title":"Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.","volume":"270","author":"Cocchi","year":"1995","journal-title":"Science"},{"key":"R33-5-20210131","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1128\/JVI.73.8.6370-6379.1999","article-title":"The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity.","volume":"73","author":"Trkola","year":"1999","journal-title":"J Virol"},{"key":"R34-5-20210131","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1073\/pnas.091056898","article-title":"Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic.","volume":"98","author":"Gonzalez","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"R35-5-20210131","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1097\/00002030-200012010-00006","article-title":"Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study.","volume":"14","author":"McDermott","year":"2000","journal-title":"AIDS"},{"key":"R36-5-20210131","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1521-6616(02)00024-4","article-title":"Reconstitution of thymic function in HIV-1 patients treated with highly active antiretroviral therapy.","volume":"106","author":"Ye","year":"2003","journal-title":"Clin Immunol"},{"issue":"Suppl 1","key":"R37-5-20210131","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/00002030-200203001-00002","article-title":"Therapeutic drug monitoring in HIV infection: current status and future directions.","volume":"16","author":"Back","year":"2002","journal-title":"AIDS"},{"key":"R38-5-20210131","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1128\/AAC.42.12.3157","article-title":"Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters.","volume":"42","author":"Srinivas","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"R39-5-20210131","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"R40-5-20210131","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/135965359800300401","article-title":"Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy.","volume":"3","author":"Burger","year":"1998","journal-title":"Antivir Ther"},{"key":"R41-5-20210131","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1097\/00002030-200307250-00016","article-title":"MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients.","volume":"17","author":"Nasi","year":"2003","journal-title":"AIDS"},{"key":"R42-5-20210131","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0140-6736(02)07276-8","article-title":"Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.","volume":"359","author":"Fellay","year":"2002","journal-title":"Lancet"},{"key":"R43-5-20210131","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/01.aids.0000161766.13782.2f","article-title":"An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children.","volume":"19","author":"Saitoh","year":"2005","journal-title":"AIDS"},{"key":"R44-5-20210131","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1097\/01.aids.0000196122.91633.04","article-title":"Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy.","volume":"19","author":"Verstuyft","year":"2005","journal-title":"AIDS"},{"key":"R45-5-20210131","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2188\/jea.2.2sup_11","article-title":"Recent scientific contributions to understanding HIV\/AIDS from the Multicenter AIDS Cohort.","volume":"2","author":"Detels","year":"1992","journal-title":"J Epidemiol"},{"key":"R46-5-20210131","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1056\/NEJM198910263211701","article-title":"A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia.","volume":"321","author":"Goedert","year":"1989","journal-title":"N Engl J Med"},{"key":"R48-5-20210131","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1126\/science.282.5395.1907","article-title":"Genetic acceleration of AIDS progression by a promoter variant of CCR5.","volume":"282","author":"Martin","year":"1998","journal-title":"Science"},{"key":"R49-5-20210131","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1001\/jama.282.8.734","article-title":"Association of the CCR5delta32 mutation with improved response to antiretroviral therapy.","volume":"282","author":"Valdez","year":"1999","journal-title":"JAMA"},{"key":"R50-5-20210131","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1097\/00002030-200012010-00020","article-title":"CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients.","volume":"14","author":"Guerin","year":"2000","journal-title":"AIDS"},{"key":"R51-5-20210131","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1468-1293.2007.00455.x","article-title":"Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.","volume":"8","author":"Laurichesse","year":"2007","journal-title":"HIV Med"},{"key":"R52-5-20210131","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/135965350501000711","article-title":"Short communication. Association of the CCR5delta32 mutation with clinical response and 5-year survival following initiation of first triple antiretroviral regimen.","volume":"10","author":"Brumme","year":"2005","journal-title":"Antivir Ther"},{"key":"R53-5-20210131","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1126\/science.272.5265.1167","article-title":"Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.","volume":"272","author":"Mellors","year":"1996","journal-title":"Science"},{"key":"R54-5-20210131","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.lab.2004.01.012","article-title":"Lack of good correlation of serum CC-chemokine levels with human immunodeficiency virus-1 disease stage and response to treatment.","volume":"143","author":"Ye","year":"2004","journal-title":"J Lab Clin Med"},{"key":"R55-5-20210131","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1086\/314522","article-title":"Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants.","volume":"178","author":"van Rij","year":"1998","journal-title":"J Infect Dis"},{"key":"R56-5-20210131","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00002030-200302140-00012","article-title":"Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection.","volume":"17","author":"Mulherin","year":"2003","journal-title":"AIDS"},{"key":"R57-5-20210131","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1006\/viro.1997.8508","article-title":"CD4-independent infection by HIV-2 (ROD\/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry.","volume":"231","author":"Reeves","year":"1997","journal-title":"Virology"},{"key":"R58-5-20210131","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00126334-200303010-00014","article-title":"Deleterious genetic influence of CX3CR1 genotypes on HIV-1 disease progression.","volume":"32","author":"Faure","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R59-5-20210131","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1172\/JCI16790","article-title":"Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans.","volume":"111","author":"McDermott","year":"2003","journal-title":"J Clin Invest"},{"key":"R60-5-20210131","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00126334-200311010-00006","article-title":"MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group Study.","volume":"34","author":"Haas","year":"2003","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00126334-200807010-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:47:23Z","timestamp":1786038443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-200807010-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,1]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31816fdc5f","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7,1]]}}}